Author(s):
Amitkumar J Vyas, Saurabh S Ray, Ajay I Patel, Ashvin V Dudhreja, Sunny R Shah, Devang B Sheth, Sandip P Dholakia
Email(s):
saurabhrai2000rs@gmail.com
DOI:
10.52711/2231-5675.2025.00033 
Address:
Amitkumar J Vyas1, Saurabh S Ray1*, Ajay I Patel1, Ashvin V Dudhreja1, Sunny R Shah1, Devang B Sheth2, Sandip P Dholakia2
1B. K. Mody Government Pharmacy College, Rajkot, Gujarat, India.
2L. M. College of Pharmacy, Ahmedabad, Gujarat, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2024
ABSTRACT:
Antibiotic resistance necessitates ongoing development against mutated microbes. This article addresses this challenge by focusing on garenoxacin, a des-fluoro-(6)-quinolone effective against diverse bacteria. Its broad spectrum and superior activity suggest wide usability.1 Studies indicate its benefits for respiratory tract infections compared to other drugs. This article presents garenoxacin's development history to understand quinolone evolution and future potential. It overviews structure, properties, synthesis, and SAR. Modifications led to improved third-generation quinolones. Microbiological and pharmacological studies, comparisons, and interaction compatibility are discussed. An analytical overview for quality management of garenoxacin synthesis and industrial production is also presented.
Cite this article:
Amitkumar J Vyas, Saurabh S Ray, Ajay I Patel, Ashvin V Dudhreja, Sunny R Shah, Devang B Sheth, Sandip P Dholakia. A Brief Overview on Chemistry, Pharmacological studies and Analysis of Garenoxacin. Asian Journal of Pharmaceutical Analysis. 2025; 15(3):206-2. doi: 10.52711/2231-5675.2025.00033
Cite(Electronic):
Amitkumar J Vyas, Saurabh S Ray, Ajay I Patel, Ashvin V Dudhreja, Sunny R Shah, Devang B Sheth, Sandip P Dholakia. A Brief Overview on Chemistry, Pharmacological studies and Analysis of Garenoxacin. Asian Journal of Pharmaceutical Analysis. 2025; 15(3):206-2. doi: 10.52711/2231-5675.2025.00033 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2024-15-3-9
REFERENCES
1. Frieri M, et al. Antibiotic resistance. J. Infect. Public Health (2016), http://dx.doi.org/10.1016/j.jiph.2016.08.007
2. Kirby, Jeffrey T., Alan H. Mutnick, Ronald N. Jones, Douglas J. Biedenbach, Michael A. Pfaller, and SENTRY Participants Group. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program 2000. Diagnostic microbiology and infectious disease. 2002; 43(4): 303-309.
3. Pereyre, S., H. Renaudin, C. Bebear, and C. M. Bébéar. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas. Antimicrobial agents and chemotherapy. 2004; 48(8): 3165-3168.
4. Edmiston Jr, Charles E., Candace J. Krepel, Karen S. Kehl, Gary R. Seabrook, Lewis B. Somberg, G. Hossein Almassi, Timothy L. Smith et al. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. Journal of Antimicrobial Chemotherapy. 2005; 56(5): 872-878.
5. Hansen, G. T., and J. M. Blondeau. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. Journal of Chemotherapy. 2005; 17(5): 484-492.
6. Zhao, Xilin, William Eisner, Nathan Perl-Rosenthal, Barry Kreiswirth, and Karl Drlica. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or-resistant Staphylococcus aureus. Antimicrobial agents and Chemotherapy. 2003; 47(3): 1023-1027.
7. Rathod, Nikita, and P. A. I. Prajapati. Analytical Method Development and Validation of Stability Indicating Method and Related Substance by Using RP-HPLC of Drug Substance. J Pharm Anal. 2018; 8(5): 367-72.
8. Taviyad, Mittal, Nilesh Patel, Urvi Chotaliya, Surendra Singh, Ashok Patel, Ajay Patel, and Amit Vyas. Chromatographic method development and validation for related substance. Pharma Science Monitor. 2017; 8(2).
9. Vyas, Amitkumar J., Chirag D. Jadav, Ajay I. Patel, Ashok B. Patel, Sunny R. Shah, Devang Sheth, and Sandip Dholakia. "Review on Stability Indicating Assay Method or Forced Degradation Study: Strategy and Regulatory Consideration." Asian Journal of Pharmaceutical Analysis. 2023; 13(2); 131-139. http://dx.doi.org/10.52711/2231-5675.2023.00022
10. Vyas, Amitkumar J., Dhruvi U. Parmar, Ashok B. Patel, Ajay I. Patel, Ashvin V. Dudhrejiya, and Sunny R. Shah. Strategic approach for HPLC Method Development and Validation. Asian Journal of Research in Pharmaceutical Sciences. 2014; 14(1): 71-76. https://doi.org/10.52711/2231-5659.2024.00011
11. Vyas, Amitkumar J., Shalini Anilkumar Jha, A. B. Patel, A. I. Patel, S. R. Shah, and D. B. Sheth. Review on simultaneous equation method (Vierodt's method). Asian Journal of Pharmaceutical Analysis. 2022; 12(2): 149-156. http://dx.doi.org/10.52711/2231-5675.2022.00026
12. Vyas, Amitkumar J., Harshal M. Vadile, Ajay I. Patel, Ashok B. Patel, Ashvin V. Dudhrejiya, Sunny R. Shah, Urvi J. Chotaliya, and Devang B. Sheth. Recent Applications of UV-Visible Derivative Spectroscopic Method. Asian Journal of Pharmaceutical Analysis. 2023; 13(2): 108-114. http://dx.doi.org/10.52711/2231-5675.2023.00019
13. Vyas, Amitkumar J., Brijesh H. Patel, Ashok B. Patel, Ajay I. Patel, and Nilesh K. Patel. A brief Review on Q-absorption Ratio Method in UV-Spectrophotometry. Asian Journal of Pharmaceutical Analysis. 2022; 12(4): 281-285. http://dx.doi.org/10.52711/2231-5675.2022.00046
14. Vyas, Amit Kumar J., Sonali B. Mishra, A. B. Patel, N. K. Patel, S. R. Shah, and D. B. Sheth. A brief review on liquid chromatography-mass spectrometry/LCMS and its application. Asian Journal of Pharmaceutical Analysis. 2022; 12(3): 203-210. http://dx.doi.org/10.52711/2231-5675.2022.00034
15. Patel, Ajay I., Kishna Ram, Swati Guttikar, Amit Kumar J. Vyas, Ashok B. Patel, Nilesh K. Patel, and Vikash Trivedi. "Rapid, sensitive and simple lc-ms/ms method development and validation for estimation of phenytoin in human plasma by using deuterated internal standard." Research Journal of pharmacy and Technology. 2021; 14(6): 2937-2944. http://dx.doi.org/10.52711/0974-360X.2021.00515
16. Patel, Ashok B., Ashish H. Asnani, Amitkumar J. Vyas, Nilesh K. Patel, Ajay I. Patel, and Arvind N. Lumbhani. A brief review on genotoxic impurities in pharmaceuticals. Asian Journal of Pharmaceutical Research. 2021; 11(3): 187-193. http://dx.doi.org/10.52711/2231-5691.2021.00034
17. Vyas, Amitkumar J., Jayshree P. Godhaniya, Ajay I. Patel, Ashok B. Patel, Nilesh K. Patel, Alpesh Chudasama, and Sunny R. Shah. A review on carcinogenic impurities found in marketed drugs and strategies for its determination by analytical methods. Asian Journal of Pharmaceutical Analysis. 2021; 11(2): 159-169. http://dx.doi.org/10.52711/2231-5675.2021.00028
18. Patel, Ashok B., Avadhi R. Bundheliya, Amitkumar J. Vyas, Nilesh K. Patel, Ajay I. Patel, and Arvind N. Lumbhani. A review on metal impurities in pharmaceuticals. Asian Journal of Pharmaceutical Analysis2021; 11(3): 212-222. http://dx.doi.org/10.52711/2231-5675.2021.00038
19. Patel, Ajay I., Anjali K. Mandavia, Amit J. Vyas, and Ashok B. Patel. Nitrosamine impurity: Management of unwelcome guest in pharma market. Asian Journal of Pharmaceutical Analysis. 2023; 13(4); 303-308. http://dx.doi.org/10.52711/2231-5675.2023.00049
20. Vyas, Amitkumar J., Sinchan M. Patel, Ashok B. Patel, Ajay I. Patel, Nilesh K. Patel, Suuny Shah, and Devang Sheth. Stability testing: An Essential study for Vaccine Formulation Development. Asian Journal of Pharmaceutical Research. 2022; 12(1): 29-36. http://dx.doi.org/10.52711/2231-5691.2022.00006
21. Vyas, Amitkumar J., Nilam M. Visana, Ajay I. Patel, Ashok B. Patel, Nilesh K. Patel, and Sunny R. Shah. Analytical quality by design in stress testing or stability-indicating method. Asian Journal of Pharmaceutical Analysis. 2021; 11(2): 170-178. http://dx.doi.org/10.52711/2231-5675.2021.00029
22. Vyas, Amitkumar J., Dhruvanshi A. Gol, Ajay I. Patel, Ashok B. Patel, Nilesh K. Patel, Jayant R. Chavda, Arvind Lumbhani, and Alpesh Chudasama. Implementing analytical quality by design (AQbD) approach for simultaneous estimation of tadalafil and macitentan by RP-HPLC method. Analytical Chemistry Letters. 2021; 11(4): 539-552. https://doi.org/10.1080/22297928.2021.1938215
23. Patel, Ajay I., Krupa B. Prajapati, Swati H. Jolapara, Amitkumar J. Vyas, Ashok B. Patel, Nilesh K. Patel, and Minakshi M. Pandey. RP-HPLC method for determination of gemfibrozil using central composite design (CCD). Research Journal of Pharmacy and Technology. 2021; 14(6): 3009-3014. http://dx.doi.org/10.52711/0974-360X.2021.00527
24. De Souza, Marcus VN. New fluoroquinolones: a class of potent antibiotics. Mini Reviews in Medicinal Chemistry. 2005; 5(11): 1009-1017.
25. Grohe, K. Zur Bedeutung des Cycloaracylierungsverfahrens für die Synthese moderner Fluorchinolone. Journal für Praktische Chemie/Chemiker‐Zeitung. 1993; 335(5): 397-409.
26. Emami, Saeed, A. Shafiei, and A. R. Foroumadi. Quinolones: recent structural and clinical developments. 2005: 123-136.
27. Domagala, John M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. Journal of Antimicrobial Chemotherapy. 1994; 33(4): 685-706.
28. Giguère, Steeve, and Patricia M. Dowling. Fluoroquinolones. Antimicrobial Therapy in Veterinary Medicine. 2013: 295-314.
29. Blondeau, Joseph M. Fluoroquinolones: mechanism of action, classification, and development of resistance. Survey of Ophthalmology. 2004; 49(2): S73-S78.
30. Liu, Xiaoqiang, Dawn M. Boothe, Kamoltip Thungrat, and Sherine Aly. Mechanisms accounting for fluoroquinolone multidrug resistance Escherichia coli isolated from companion animals. Veterinary Microbiology. 2012; 161(1-2): 159-168.
31. Kümmerer, Klaus, ed. Pharmaceuticals in the environment: sources, fate, effects and risks. Springer Science and Business Media. 2008.
32. Kümmerer, Klaus. Significance of antibiotics in the environment. Journal of Antimicrobial Chemotherapy. 2003; 52(1): 5-7.
33. PubChem CID: 124093. https://pubchem.ncbi.nlm.nih.gov
34. Douglas SJ., Jie JL. The Art of Drug Synthesis; A John Wiley and Sons, INC., Pubication, New Jersey, 2007. 64.
35. Raut CN., Avani CHS. World Intellectual Property Organisation, International Bureau. International Publication Number: WO 2013/121439 A2, 2013.
36. Yozo T, Kazuya H, Masahiro T, Yasuo W. Quinolonecarboxylic acid derivatives or salts Thereof. United States Patent USP 6025370, 2000.
37. Minoru Y, Shiochi H, Kazuya H, Kazuko T, Hiroko M, Minako Y, Kenji Y, Katsuji O, Tamotsu T, Kyoko T, Hirohiko Y, Taro K, Hironori K. Process for producing 7-isoindolinequinolonecarboxylic derivatives and intermediates thereof, salts of 7-isoindolinequinolonecarboxylic acids, Hydrates thereof, and composition of containing the same as active ingredient. United States Patent USP 6337399 B1, 2002.
38. Roig, Jorge, Josep M. Arnau, Antoni Vallano, and Jordi Rello. New developments in therapeutic agents for Legionnaires' disease. Anti-Infective Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Infective Agents). 2007; 6(4): 228-242.
39. Pham, Thu DM, Zyta M. Ziora, and Mark AT Blaskovich. Quinolone antibiotics. Medchemcomm. 2019; 10(10): 1719-1739.
40. Andersson, Monique I., and Alasdair P. MacGowan. Development of the quinolones. Journal of Antimicrobial Chemotherapy. 2003; 51(suppl_1): 1-11.
41. Withdrawal assessment report for Garenoxacin Mesylate (garenoxacin). Pre-authorisation Evaluation of Medicines for Human Use, European Medicines Agency, London. Doc. Ref: EMEA/CHMP/363573/2007, 2007.
42. Hooper, David C. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clinical Infectious Diseases. 2001; 32(Supplement_1): S9-S15.
43. Wu, P., Lawrence, L.E., Denbleyker, K.L. and Barrett, J.F. Mechanism of action of the des-F (6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays. Antimicrobial Agents and Chemotherapy. 2001; 45(12): 3660-3662.
44. Ince, D., Zhang, X., Silver, L.C. and Hooper, D.C. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrobial Agents and Chemotherapy. 2002; 46(11): 3370-3380.
45. Yamagishi, Yuka, Tatsuya Shibata, Satoshi Nakagawa, Nobuhiko Nomura, Junichi Mitsuyama, and Hiroshige Mikamo. Proposed pharmacokinetic-pharmacodynamic breakpoint of garenoxacin and other quinolones. Japanese Journal of Infectious Diseases. 2017; 70(6): 616-620.
46. Lister PD. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F (6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. Journal of Antimicrobial Chemotherapy. 2003; 51: 199-202. DOI: 10.1093/jac/dkg017===Eur J Clin Pharmacol (2012) 68: 39-53 DOI 10.1007/s00228-011-1095-3
47. Ricci, Vito, and Laura Piddock. Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones. Journal of Antimicrobial Chemotherapy. 2003; 52(4): 605-609.
48. Credito, Kim L., Michael R. Jacobs, and Peter C. Appelbaum. Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents. Antimicrobial Agents and Chemotherapy. 2003; 47(4): 1399-1402.
49. Andrews, J., D. Honeybourne, G. Jevons, M. Boyce, R. Wise, A. Bello, and D. Gajjar. Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. Journal of Antimicrobial Chemotherapy. 2003; 51(3): 727-730.
50. Krishna, Gopal, Mark H. Gotfried, Kenneth Rolston, and Zaiqi Wang. Penetration of garenoxacin into lung tissues and bone in subjects undergoing lung biopsy or resection. Current Medical Research and Opinion. 2007; 23(8): 1841-1847.
51. Edmiston, Charles E., Candace J. Krepel, Gary R. Seabrook, Jonathan B. Towne, Timothy L. Smith, Todd A. Loehrl, P. Ashley Wackym et al. Tissue and fluid penetration of garenoxacin in surgical patients. Surgical Infections. 2007; 8(2): 179-188.
52. Hayakawa, Hiroyoshi, Yoko Fukushima, Hiroshi Kato, Hiroyuki Fukumoto, Takumi Kadota, Hiroyuki Yamamoto, Hiroyuki Kuroiwa, Junko Nishigaki, and Akira Tsuji. Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. Drug Metabolism and Disposition. 2003; 31(11): 1409-1418.
53. Takagi, Hiroyasu, Kiyoshi Tanaka, Hisatsugu Tsuda, and Hiroyuki Kobayashi. Clinical studies of garenoxacin. International Journal of Antimicrobial Agents. 2008; 32(6): 468-474.
54. Tanigawara, Yusuke, Kenji Nozawa, and Hisatsugu Tsuda. Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation. European Journal of Clinical Pharmacology. 2012; 68: 39-53.
55. Padmanaban, Anantha, K. Krishnaprasad, Shreyas Lathi, and Amit Bhargava. A case-cohort study on clinical utility of garenoxacin mesylate in respiratory tract infections: A retrospective analyses. International Journal of Scientific Study. 2014; 2(7): 136-140.
56. Sinha, Ajay Kumar, Bhavana Srivastava, Dinesh Chand Punera, and Renu Khanchandani. Comparative study of efficacy and safety of garenoxacin and moxifloxacin in acute exacerbation of chronic bronchitis in COPD patients. 2018.
57. Aronson JK. MEYLER’S Side Effects of Drugs, Volume 01, 16th edition. Elsevier. pp 512.
58. Wang, Zaiqi, Dennis M. Grasela, and Gopal Krishna. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers. Clinical Therapeutics. 2007; 29(6): 1098-1106.
59. Wang, Zaiqi, Dennis M. Grasela, and Gopal Krishna. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers. Clinical Therapeutics. 2007; 29(6): 1098-1106.
60. Kappel, Eva Maria, Mehdi Shakibaei, Akintunde Bello, and Ralf Stahlmann. Effects of the des-F (6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats. Antimicrobial Agents and Chemotherapy. 2002; 46(10): 3320-3322.
61. Krishna, Gopal, James C. Kisicki, Steven Olsen, Dennis M. Grasela, and Zaiqi Wang. Effect of an aluminum‐and magnesium‐containing antacid on the bioavailability of garenoxacin in healthy volunteers. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2007; 27(7): 963-969.
62. Yamagishi, Yuka, Mao Hagihara, Hamada, Kimura, Hirokazu Imai, and Mikamo. Pharmacokinetic study of garenoxacin in severe renal failure patients. Jpn J Antibiot. 2015; 68: 141-50.
63. Krishna, Gopal, James C. Kisicki, Steven Olsen, Dennis M. Grasela, and Zaiqi Wang. The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers. The Journal of Clinical Pharmacology. 2007; 47(5): 628-632.
64. Azhakesan, Ajitha, and Sujatha Kuppusamy. QbD-Based Development and Validation of Novel Stability-Indicating Method for the Assay and Dissolution of Garenoxacin in Garenoxacin Tablets. Journal of AOAC International. 2022; 105; 2: 370-378.
65. Jurado, J. M., and J. A. Ocana. Fluorometric determination of mixtures of quinolones by means of partial least squares and neural networks. Analytical Sciences. 2007; 23(3): 337-341.
66. Edlabadkar, A. P., and A. P. Rajput. Development of Four Simple UV-Spectrophotometry Methods for Estimation of Garenoxacin Mesylate in Bulk Material and in Pharmaceutical Formulation. Der Pharmacia Lettre. 2016; 8: 213.
67. National Centre for Biotechnology Information. Pubchem Compound summary for CID 124093, Garenoxacin. 2023.